Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work: JAKi, TNFi quicker than tocilizumab, abatacept Even though they all get to a similar place eventually, some get there quicker (but worth any safety tradeoffs?) #ACR24 ABST0501 @RheumNow https://t.co/YVpTBMe3gi

• https://x.com/drdavidliew/status/1857781834710417896/photo/1

Spatial Proteomics study for TEN Marked enrichment of type I and II interferon and STAT1 activation Pathways suggests benefit for JAKi in this condition Clinical response in case photos, suggests benefit of pursuing clinical trial Year in Review #ACR24 Bridges @RheumNow https://t.co/K34lbnenRH

• https://x.com/ericdeinmd/status/1857781408774643904/photo/1
• https://x.com/ericdeinmd/status/1857781408774643904/photo/1
• https://x.com/ericdeinmd/status/1857781408774643904/photo/1

Have you ever tried giving Semaglutide in addressing weight loss among your patients with #osteoarthritis and #obesity? @RheumNow #ACR

Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings. Whether all of this is appropriate or not, we'll have to see... #ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5

• https://x.com/drdavidliew/status/1857779835030089902/photo/1

#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9

• https://x.com/i/web/status/1857779533933396132
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1

Synovial fibroblast gene expression Neutron-4 - plays role in axonal outgrowth, affects pain-sensitive neurons May help explain pain in RA, possible targets Year in Review #ACR24 Bridges @RheumNow https://t.co/kpDVKh0C9O

• https://x.com/ericdeinmd/status/1857777963359412655/photo/1
• https://x.com/ericdeinmd/status/1857777963359412655/photo/1
• https://x.com/ericdeinmd/status/1857777963359412655/photo/1

Role of X chromosome in autoimmune disease? SLE increased in Klinefelter (XXY), decreased in Turner’s (XO) X chromosome inactivation with Xist Inductively transgenic expression of Xist in male mice induces autoantibodies Year in Review #ACR24 Bridges @RheumNow https://t.co/M88f0v0kpe

• https://x.com/ericdeinmd/status/1857778994533351769/photo/1
• https://x.com/ericdeinmd/status/1857778994533351769/photo/1
• https://x.com/ericdeinmd/status/1857778994533351769/photo/1
• https://x.com/ericdeinmd/status/1857778994533351769/photo/1

Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients! Don’t forget the 5Ms! 🧠Mind (cog/mood) 💊Medication (PIM) 🏃‍♀️Mobility 👉Multi-complexity 💪🏻Matters most (pt priority) @RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX

• https://x.com/DrTrishHarkins/status/1857427999248863574/photo/1
• https://x.com/DrTrishHarkins/status/1857427999248863574/photo/1
• https://x.com/DrTrishHarkins/status/1857427999248863574/photo/1

CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD

• https://x.com/MartinezZayasMd/status/1857506727580557397/photo/1

EGPA: To RTX or not to RTX? French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy Huge anticipation for these results, hopefully next year! #ACR24 @RheumNow https://t.co/POelLpirrI

• https://x.com/Dr_Brian_MD/status/1857484737084047833/photo/1

SCN9A: Mutations associated with primary erythromelalgia, loss of fxn in congenital inability to experience pain Target for OA? Nav1.7 expressed in human OA chondrocytes Blocking in mice- decr structural jt damage, incr mouse movement Bridges Year in Review #ACR24 @RheumNow https://t.co/AKViXGfDa6

• https://x.com/ericdeinmd/status/1857776605248082430/photo/1
• https://x.com/ericdeinmd/status/1857776605248082430/photo/1
• https://x.com/ericdeinmd/status/1857776605248082430/photo/1

Hot off the racks: The MITIGATE trial is the 1st RCT for IgG4-RD showing that Inebilizumab significantly reduced flare rates vs PbO by depleting CD19-targeted B cells Game changer? Year in review. @RheumNow #ACR24 @rheumarhyme @marklagacmd @idatan @ljdado https://t.co/CZvdrymIyr

• https://x.com/RHEUMarampa/status/1857776021438595250/photo/1
• https://x.com/RHEUMarampa/status/1857776021438595250/photo/1

Treatment alert for Sjogrens TWINSS study: Iscalimab CD40/CD40L monoclonal Ab: Improves disease activity Also helps fatigue and sicca, not pain Dazodalibep - CD40L antagonist also reduce symptoms/disease activity Year in Review #ACR24 Pillinger @RheumNow https://t.co/WjHuEpm9XW

• https://x.com/ericdeinmd/status/1857773972567265417/photo/1
• https://x.com/ericdeinmd/status/1857773972567265417/photo/1
• https://x.com/ericdeinmd/status/1857773972567265417/photo/1
• https://x.com/ericdeinmd/status/1857773972567265417/photo/1

Year in review: The MANDARA trial showed benralizumab was non-inferior to mepolizumab for #EGPA @RheumNow #ACR24 @rheumarhyme @doktora_ging https://t.co/k5azGQOECB

• https://x.com/RHEUMarampa/status/1857773694761762864/photo/1
• https://x.com/RHEUMarampa/status/1857773694761762864/photo/1

Looking forward to this Plenary - upadacitinib vs plbo in GCA Similar to GiACTA, 26wk taper w/UPA better than 52wk taper w/PLBO. Too small for safety, but no new rsks Strong argument for DMARDs upfront in GCA... but doesn't help with which 😉 #ACR24 @RheumNow Abstr#0770 https://t.co/MZY4QUazhI

• https://x.com/EBRheum/status/1857773615619453431/photo/1
• https://x.com/EBRheum/status/1857773615619453431/photo/1